Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hyperostosis corticalis generalisata, also known as van Buchem disease, is a rare craniotubular hyperostosis characterized by hyperostosis of the skull, mandible, clavicles, ribs and diaphyses of the long bones, as well as the tubular bones of the hands and feet. Clinical manifestations include increased skull thickness with cranial nerve entrapment causing inconsistent cranial nerve palsies.
Features include: Cranial nerve paralysis, Hearing loss (hearing impairment), Optic atrophy from cranial nerve compression, and Thickened cortex of long bones and 5 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Cranial nerve paralysis, Optic atrophy from cranial nerve compression, Headache |
SOST-related sclerosteosis and SOST-related endosteal hyperostosis, van Buchem type (van Buchem disease) are clinically and radiographically similar disorders of progressive bone overgrowth due to increased bone formation. The disorders differ in severity and in type of molecular genetic variants.
SOST-related sclerosing bone dysplasias should be suspected in individuals with the following findings.
Clinical findings
Source: GeneReviews —
No approved treatments are currently available for hyperostosis corticalis generalisata. The disease remains an area of unmet medical need.
No clinical practice guidelines for SOST-related sclerosing bone dysplasias have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with these disorders. Evaluations Following Initial Diagnosis To establish the extent of disease in an individual diagnosed with a SOST-related sclerosing bone dysplasia, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. SOST-Related Sclerosing Bone Dysplasias: Recommended Evaluations Following Initial Diagnosis
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. SOST-Related Sclerosing Bone Dysplasias: Recommended Surveillance
No clinical trials have been registered for hyperostosis corticalis generalisata.
118 publications have been identified in PubMed for hyperostosis corticalis generalisata. Research spans Review / Meta-Analysis (25%), Basic Science / Preclinical (25%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 30 | 25% |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 12:59 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Bones and joints
2 |
Thickened cortex of long bones, Increased bone density (increased bone mineral density) |
Lab test results | 2 | Elevated circulating alkaline phosphatase concentration, Elevated circulating type I procollagen aminoterminal propeptide concentration |
Ears | 1 | Hearing loss (hearing impairment) |
Eyes | 1 | Optic atrophy from cranial nerve compression |
Muscles | 1 | Optic atrophy from cranial nerve compression |
SOST-related sclerosteosis and SOST-related endosteal hyperostosis, van Buchem type (van Buchem disease) have very similar phenotypes. However, the manifestations of van Buchem disease are generally milder than those in sclerosteosis . To date, more than 100 individuals have been identified with biallelic pathogenic variants in SOST or a biallelic 52-kb deletion downstream of SOST. The following description of the phenotypic features associated with this condition is based on these reports. Table 2. SOST-Related Sclerosing Bone Dysplasias: Comparison of Phenotypes by Select Features
Feature | Sclerosteosis(n=96) | Van Buchem Disease(n=31) | Comment |
|---|---|---|---|
Linear overgrowth | 100% | 0% | Normal stature in van Buchem disease |
Hearing loss | 94% | 78% | — |
Facial palsies | 93% | 89% | — |
Cranial hyperostosis causing facial distortion | 90% | 68% | Typically only prominent mandible in van Buchem disease |
Increased intracranial pressure | 71% | 16% | — |
Syndactyly | 66% | 0% | No syndactyly in van Buchem disease Modified from and Tall stature. Accelerated linear growth becomes evident in early childhood. Longitudinal growth arrests at puberty, by which time individuals can reach heights exceeding two meters (6.5 feet). |
Source: GeneReviews — "SOST-Related Sclerosing Bone Dysplasias"
SOST-related sclerosing bone dysplasias must be distinguished from other sclerosing bone dysplasias, including: • The osteoscleroses, notably osteopetrosis, characterized by increased bone density with no bone overgrowth and little or no disturbance of the contours of the bones; • The craniotubular dysplasias, characterized by abnormal modeling of the skeleton and moderate sclerosis of the calvarium and base of the skull. The predominant feature of the craniotubular hyperostoses is overgrowth of bone, which leads to alterations of contours and increase in radiologic density of the skeleton. The bones are often very resistant to trauma. In addition to SOST-related sclerosing bone dysplasias, this group of disorders includes the conditions summarized in . Table 3. Other Craniotubular Hyperostoses to Consider in the Differential Diagnosis of SOST-Related Sclerosing Bone Dysplasias
Gene | Disorder | MOI | Features of Disorder |
|---|---|---|---|
LRP4 | LRP4-related sclerosteosis (OMIM 614305) | ADAR | Hyperostosis of long bones skull; Facial deformity; Cranial nerve impingement hearing loss; Tall stature |
LRP5 | Endosteal hyperostosis, Worth type (OMIM 144750) | AD | Hyperostosis of long bones skull; Cranial nerve impingement hearing loss; Enlargement of mandible |
No syndactyly SOST1 | SOST-related craniodiaphyseal dysplasia | AD | Hyperostosis of skull; Facial deformity w/hypertelorism; Cranial nerve impingement hearing loss |
No syndactyly SP72 | SP7-related craniodiaphyseal dysplasia | AR | Facial dysmorphism; Severe hyperostosis of calvarium, skull base, mandible |
1 of 2 persons reported had recurrent fractures. TGFB13 | TGFB1-related Camurati-Engelmann diaphyseal dysplasia (See Camurati-Engelmann Disease.) | AD | Hyperostosis of long bones; Frontal bossing, enlargement of mandible, proptosis, cranial nerve impingement later in life in those w/severe disease |
Source: GeneReviews — "SOST-Related Sclerosing Bone Dysplasias"
Biomarker and diagnostic research for hyperostosis corticalis generalisata has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Hearing | Formal audiologic eval | Neurologic |
Ophthalmologic | Ophthalmologic eval for evidence of intracranial pressure /or proptosis | — |
Dental | Dental /or orthodontic eval for malalignment malocclusion in children | — |
Genetic counseling | By genetics professionals1 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of SOST-related sclerosing bone dysplasias to facilitate medical personal decision making DXA = dual-energy x-ray absorptiometry; MOI = mode of inheritance 1. |
SOST-Related Sclerosing Bone Dysplasias: Treatment of Manifestations Manifestation/Concern | Treatment | Considerations/Other Hearing loss |
Cranial nerve entrapment | Surgical decompression as needed for recurrent facial paralysis or facial pain | May be needed from age 2 yrs onward |
Mandibular overgrowth | Surgical reduction | May be performed for cosmetic reasons or if mouth closure is impaired due to mandible overgrowth; Tooth extraction may be difficult.; Mgmt by an orthodontic or craniofacial team is recommended. |
Proptosis | Orbital decompression | In adulthood |
Dental manifestations | Treatment per orthodontist /or as part of craniofacial team | Increased intracranial pressure |
Syndactyly | Surgical correction | May be necessary in early childhood to improve function cosmetic appearance To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. |
Source: GeneReviews — "SOST-Related Sclerosing Bone Dysplasias"
Avoid agents known to suppress bone resorption:
Bisphosphonates
Denosumab
Selective estrogen receptor modulators
Avoid agents known to stimulate bone formation:
Teriparatide
Abaloparatide
Romozosumab
Source: GeneReviews — "SOST-Related Sclerosing Bone Dysplasias"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "SOST-Related Sclerosing Bone Dysplasias"
View trials for hyperostosis corticalis generalisata
Evaluation |
|---|
Frequency1 |
|---|
Bone mass | DXA scan to assess bone mineral density2 | Intermittently until age 18 yrs; Every 5 yrs in adults Biochemical markers of bone turnover:3; Serum P1NP, alkaline phosphatase, osteocalcin; Urine NTX serum CTX |
Hearing | Audiologic assessment | Annually in childhood; As needed in adults |
Neurologic | Exam for evidence of cranial nerve entrapment intracranial pressure | Every 6 mos until age 18 yrs; Annually in adults |
Ophthalmologic | Ophthalmologic exam to assess for proptosis, intraocular pressure, eval of optic nerve papilla | Annually |
Teeth | Dental orthodontic eval of tooth malalignment malocclusion | Annually until age 18 yrs CTX = type I collagen cross-linked C-terminal telopeptide; NTX = type I collagen cross-linked N-terminal telopeptide; P1NP = procollagen type 1 amino terminal propeptide 1. |
Source: GeneReviews — "SOST-Related Sclerosing Bone Dysplasias"
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
Laboratory research
30 |
25% |
Patient case studies | 20 | 17% |
Disease patterns and progression | 18 | 15% |
Testing and diagnosis research | 8 | 7% |
Clinical study results | 6 | 5% |
New treatment approaches | 6 | 5% |
Young RE (2026). [PMID: 40931319](https://pubmed.ncbi.nlm.nih.gov/40931319/). *Clin Genet*. [Epidemiology / Natural History]
Econs MJ (2026). [PMID: 40913471](https://pubmed.ncbi.nlm.nih.gov/40913471/). *J Bone Miner Res*. [Epidemiology / Natural History]
Albuquerque ALB (2026). [PMID: 41424367](https://pubmed.ncbi.nlm.nih.gov/41424367/). *Genet Med*. [Review / Meta-Analysis]
Liu W (2026). [PMID: 41071584](https://pubmed.ncbi.nlm.nih.gov/41071584/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]
Alves I (2026). [PMID: 41559786](https://pubmed.ncbi.nlm.nih.gov/41559786/). *Orphanet J Rare Dis*. [Review / Meta-Analysis]
Pfirrmann C (2026). [PMID: 40998114](https://pubmed.ncbi.nlm.nih.gov/40998114/). *Orthop Traumatol Surg Res*. [Review / Meta-Analysis]
Deen Hayatu M (2026). [PMID: 41563457](https://pubmed.ncbi.nlm.nih.gov/41563457/). *Z Rheumatol*. [Review / Meta-Analysis]
Horike N (2026). [PMID: 41748604](https://pubmed.ncbi.nlm.nih.gov/41748604/). *Nat Commun*. [Basic Science / Preclinical]
Zhytnik L (2026). [PMID: 41051363](https://pubmed.ncbi.nlm.nih.gov/41051363/). *J Bone Miner Res*. [Basic Science / Preclinical]
Savarirayan R (2026). [PMID: 41247754](https://pubmed.ncbi.nlm.nih.gov/41247754/). *JAMA Pediatr*. [Clinical Trial Publication]